Trials / NCT01505062
Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B
Terminated Phase 1 / Phase 2 Gene therapy
Why it stopped: Study stopped not for safety reasons. Due to review of clinical development plans and priorities, Sponsor decided to stop development of the product.
- Sponsor
- Sanofi
- Treatment
- SAR421869
- Gene
- Not stated
- Conditions
- Usher Syndrome, Retinitis Pigmentosa
- Ages
- 6 Years to no upper limit
- Enrollment
- 9 participants
- Started
- 2012-03-26
- Main results expected
- 2019-08-16
- Results posted
- Yes
- Record last updated
- 2022-04-28
What the study is testing
To evaluate the safety and tolerability of ascending doses of subretinal injections of SAR421869 in participants with Usher syndrome type 1B.
To evaluate for possible biological activity of SAR421869.
Where it runs
France (1)
- Investigational Site Number 250001, Paris
United States (1)
- Investigational Site Number 840001, Portland, Oregon